Vol. 23/No. 10 | Oncology Live®

May 27, 2022

Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.

May 26, 2022

In the context of checkpoint blockade in nasopharyngeal carcinoma, the results of the phase 3 RATIONALE-309 trial support earlier findings of the role immunotherapy may play for patients in the first line.

May 25, 2022

A panel of hepatobiliary tumor experts discuss several pivotal phase 3 clinical trials examining combination approaches that have expanded or are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable hepatocellular carcinoma.

May 24, 2022

The prevalence of ESR1 mutations in endocrine-resistant metastatic breast cancer has paved an avenue for investigators to explore their role in the promotion of metastasis.

May 23, 2022

The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.

May 20, 2022

For decades in cancer care, the compiling of patient-reported outcomes was limited to simple standardized questionnaires completed with pen and paper.

May 19, 2022

Developing a system with a patient-centric focus, investigators at Yale Cancer Center and Moffitt Cancer Center initiated pilot programs to offer patients better access to care following a diagnosis of cancer.

May 17, 2022

Despite numerous well-designed and conducted randomized trials, a definitive answer to the role of specific disease management remains unclear, particularly in the discussions of the optimal role for the regional delivery of cytotoxic chemotherapy in the treatment of patients with ovarian cancer.